{
    "clinical_study": {
        "@rank": "124575", 
        "arm_group": [
            {
                "arm_group_label": "Glubran 2", 
                "arm_group_type": "Experimental", 
                "description": "Glubran 2 will be used at end of surgery"
            }, 
            {
                "arm_group_label": "Standard Surgery", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "Glubran 2 as a surgical glue maybe effective in reducing seroma formation post axillary\n      dissection in breast cancer patients."
        }, 
        "brief_title": "Effectivenes of Cyanoacrylate (Glubran 2\u00ae) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Seroma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The Patient should be above 18 years old\n\n          -  The Patients has Node positive breast cancer\n\n          -  The Patient is eligible for axillary dissection in addition to a surgical\n             intervention for the primary tumor\n\n          -  Patients whose sentinel lymph nodes test positive during surgery.\n\n          -  The patient is willing to sign an informed consent to participation\n\n        Exclusion Criteria:\n\n          -  Platelet count is less than 100000\n\n          -  Obese patients with a BMI of more than 35\n\n          -  Patients who need immediate breast reconstruction surgery\n\n          -  Patients who are receiving anticoagulation therapy or have coagulation disorders\n\n          -  Pregnant or lactating patients\n\n          -  Patients who are on steroid therapy\n\n          -  Patients who received chest radiotherapy\n\n          -  Patients who received neoadjuvant chemotherapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141373", 
            "org_study_id": "PRT-CTU-0912/03 Version 5.0"
        }, 
        "intervention": {
            "arm_group_label": "Glubran 2", 
            "intervention_name": "Glubran 2", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "seroma", 
            "axillary", 
            "dissection"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Amman", 
                    "country": "Jordan", 
                    "zip": "1269 /11941"
                }, 
                "name": "King Hussein Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Faiez Daoud, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mohammed Hamdan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mahmoud Al-Masri, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Jordan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effectivenes of Cyanoacrylate (Glubran 2\u00ae) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection", 
        "overall_contact": {
            "email": "Malmasri@KHCC.JO", 
            "last_name": "Mahmoud AlMasri, MD", 
            "phone": "009625300460"
        }, 
        "overall_official": {
            "affiliation": "King Hussein Cancer Center", 
            "last_name": "Mahmoud Al Masri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Jordan: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Total drainage volume", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Total seroma aspirate volume", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141373"
        }, 
        "responsible_party": {
            "investigator_affiliation": "King Hussein Cancer Center", 
            "investigator_full_name": "Mahmoud Al-Masri", 
            "investigator_title": "Chairman, Department of Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Duration of fluid drainage", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Time to drain removal", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Number of seroma aspirations", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Additional costs incurred due to the need of aspirations", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "King Hussein Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "King Hussein Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}